XHKG2235
Market cap325mUSD
Dec 27, Last price
5.98HKD
1D
-0.33%
1Q
49.50%
IPO
-80.39%
Name
MicroTech Medical Hangzhou Co Ltd
Chart & Performance
P/E
—
P/S
9.55
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
248m
+43.10%
Net income
0k
P
CFO
0k
P
Earnings
May 16, 2025
Profile
MicroTech Medical (Hangzhou) Co., Ltd. engages in the research and development, manufacture, and commercialization of diabetes management medical devices and consumables in the People's Republic of China and internationally. Its products include Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, blood glucose monitoring systems, and closed-loop artificial pancreas. The company is also involved in engineering and technology research experimentation and development activities. MicroTech Medical (Hangzhou) Co., Ltd. was incorporated in 2011 and is headquartered in Hangzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 248,346 43.10% | 173,543 14.62% | 151,404 101.13% | ||
Cost of revenue | 356,743 | 283,468 | 189,612 | ||
Unusual Expense (Income) | |||||
NOPBT | (108,397) | (109,925) | (38,208) | ||
NOPBT Margin | |||||
Operating Taxes | 164 | 2,702 | 29 | ||
Tax Rate | |||||
NOPAT | (108,560) | (112,627) | (38,237) | ||
Net income | (37,745) -21.66% | (48,182) -58.29% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (22,903) | 1,657,387 | |||
BB yield | 0.84% | -18.90% | |||
| Debt | |||||
Debt current | 4,896 | 453 | 115 | ||
Long-term debt | 809 | 981 | 395 | ||
Deferred revenue | 11 | ||||
Other long-term liabilities | 4,153 | 2,626 | |||
Net debt | (1,885,371) | (2,045,136) | (2,150,468) | ||
| Cash flow | |||||
Cash from operating activities | (107,674) | (44,216) | |||
CAPEX | (29,779) | (18,721) | |||
Cash from investing activities | (965,582) | 97,688 | |||
Cash from financing activities | (23,464) | (20,572) | 1,574,183 | ||
FCF | (105,538) | (184,367) | 44,146 | ||
| Balance | |||||
Cash | 1,891,075 | 2,046,570 | 2,150,978 | ||
Long term investments | |||||
Excess cash | 1,878,658 | 2,037,893 | 2,143,408 | ||
Stockholders' equity | 425,743 | 405,054 | 522,337 | ||
Invested Capital | 1,644,556 | 1,808,406 | 1,722,110 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 425,683 | 425,743 | 373,165 | ||
Price | 6.40 -34.36% | 9.75 -58.51% | 23.50 | ||
Market cap | 2,724,372 -34.37% | 4,150,990 -52.66% | 8,769,376 | ||
EV | 839,001 | 2,105,854 | 6,618,908 | ||
EBITDA | (97,223) | (99,442) | (29,876) | ||
EV/EBITDA | |||||
Interest | 313 | 147 | 17 | ||
Interest/NOPBT | |||||